Apollomics Inc. Class A Ordinary Shares Net Assets
Apollomics Inc. Class A Ordinary Shares net assets. Based on the latest financial reports, Apollomics Inc. Class A Ordinary Shares (APLM) has net assets worth $-3.19 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.71 Million) and total liabilities ($9.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Apollomics Inc. Class A Ordinary Shares equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.19 Million |
| % of Total Assets | -47.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 38.67 |
Net Assets of Apollomics Inc. Class A Ordinary Shares (2019–2025)
Net assets of Apollomics Inc. Class A Ordinary Shares from 2019 to 2025. This chart illustrates how Apollomics Inc. Class A Ordinary Shares's net assets have evolved over time, based on quarterly financial data. See Apollomics Inc. Class A Ordinary Shares net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Apollomics Inc. Class A Ordinary Shares (2019–2025)
The table below shows the annual net assets of Apollomics Inc. Class A Ordinary Shares from 2019 to 2025. For live market cap and overall valuation, see APLM market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-3.19 Million | -165.54% |
| 2024-12-31 | $4.86 Million | -88.20% |
| 2023-12-31 | $41.23 Million | +109.20% |
| 2022-12-31 | $-448.12 Million | -110.52% |
| 2021-12-31 | $-212.86 Million | -66.39% |
| 2020-12-31 | $-127.93 Million | -110.69% |
| 2019-12-31 | $-60.72 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Apollomics Inc. Class A Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64503100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Apollomics Inc. Class A Ordinary Shares Net Assets Breakdown (December 2025)
Apollomics Inc. Class A Ordinary Shares net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $21.00K | % |
| Other Comprehensive Income | $3.44 Million | % |
| Other Components | $705.12 Million | % |
| Total Equity | $-3.19 Million | 100.00% |
Apollomics Inc. Class A Ordinary Shares Competitors by Market Cap
The table below lists competitors of Apollomics Inc. Class A Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Molinos Juan Semino SA
BA:SEMI
|
$30.09 Million |
|
Malin Corporation plc
IR:MLC
|
$30.09 Million |
|
Alakasa Industrindo Tbk
JK:ALKA
|
$30.10 Million |
|
WebCash Corporation
KQ:053580
|
$30.11 Million |
|
E&E Recycling
TWO:8440
|
$30.08 Million |
|
Scanwolf Corporation Bhd
KLSE:7239
|
$30.08 Million |
|
KCP Sugar and Industries Corporation Limited
NSE:KCPSUGIND
|
$30.05 Million |
|
JAS Asset PCL
BK:J
|
$30.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apollomics Inc. Class A Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,864,000 to -3,188,000, a change of -8,052,000 (-165.5%).
- Net loss of 10,939,000 reduced equity.
- Other factors increased equity by 2,887,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.94 Million | -343.13% |
| Other Changes | $2.89 Million | +90.56% |
| Total Change | $- | -165.54% |
Book Value vs Market Value Analysis
This analysis compares Apollomics Inc. Class A Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-69.96 | $20.84 | x |
| 2020-12-31 | $-147.40 | $20.84 | x |
| 2021-12-31 | $-245.24 | $20.84 | x |
| 2022-12-31 | $-516.29 | $20.84 | x |
| 2023-12-31 | $55.42 | $20.84 | x |
| 2024-12-31 | $5.25 | $20.84 | x |
| 2025-12-31 | $-2.21 | $20.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apollomics Inc. Class A Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -128.69%
- • Asset Turnover: 1.27x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-217.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-39.83 Million |
| 2020 | 0.00% | -4070.73% | 0.01x | 0.00x | $-62.03 Million |
| 2021 | 0.00% | -4739850.00% | 0.00x | 0.00x | $-73.51 Million |
| 2022 | 0.00% | -74554.49% | 0.00x | 0.00x | $-196.00 Million |
| 2023 | -418.59% | -21023.26% | 0.01x | 1.34x | $-176.72 Million |
| 2024 | -1107.28% | -27201.01% | 0.02x | 2.69x | $-54.34 Million |
| 2025 | 0.00% | -128.69% | 1.27x | 0.00x | $-10.62 Million |
Industry Comparison
This section compares Apollomics Inc. Class A Ordinary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Apollomics Inc. Class A Ordinary Shares (APLM) | $-3.19 Million | 0.00% | N/A | $30.09 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung… Read more